Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.

Puntmann VO, Nagel E, Beitzke D, Kammerlander A, Voges I, Doerr M, Chamling B, Bozkurt B, Kaski JC, Spatz E, Herrmann E, Rohde G, DeLeuw P, Windemuth-Kieselbach C, Eckhardt S, Taylor PC, Berry C

Open source

DOI
10.1038/s41467-026-75991-w
Published
2026 Jul 30
Container
Nature communications
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-75991-w,
  title = {Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.},
  author = {Puntmann VO and Nagel E and Beitzke D and Kammerlander A and Voges I and Doerr M and Chamling B and Bozkurt B and Kaski JC and Spatz E and Herrmann E and Rohde G and DeLeuw P and Windemuth-Kieselbach C and Eckhardt S and Taylor PC and Berry C},
  year = {2026},
  journal = {Nature communications},
  doi = {10.1038/s41467-026-75991-w},
  url = {https://doi.org/10.1038/s41467-026-75991-w}
}

RIS

TY  - JOUR
TI  - Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.
AU  - Puntmann VO
AU  - Nagel E
AU  - Beitzke D
AU  - Kammerlander A
AU  - Voges I
AU  - Doerr M
AU  - Chamling B
AU  - Bozkurt B
AU  - Kaski JC
AU  - Spatz E
AU  - Herrmann E
AU  - Rohde G
AU  - DeLeuw P
AU  - Windemuth-Kieselbach C
AU  - Eckhardt S
AU  - Taylor PC
AU  - Berry C
PY  - 2026
JO  - Nature communications
DO  - 10.1038/s41467-026-75991-w
UR  - https://doi.org/10.1038/s41467-026-75991-w
ER  - 

APA

VO, P., E, N., D, B., A, K., I, V., M, D., B, C., B, B., JC, K., E, S., E, H., G, R., P, D., C, W., S, E., PC, T., & C, B. (2026). Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.. Nature communications. https://doi.org/10.1038/s41467-026-75991-w

Source records